May. 18 at 6:11 PM
$TSHA TSHA pulled back from
$7 to about
$5.40 range after earnings, but the next 6 weeks are huge. We’re getting one-year data from the first 12 patients, completion of dosing in the pivotal REVEAL trial, and completion of dosing in the ASPIRE study for the younger kids — all by end of June. Solid cash runway into 2028 and clean FDA alignment. Plus, Vestal Point Capital just filed a 13G showing they now own 18 million shares (6.3% stake), up from their previous 5%. If the data hits, this drop could look like a gift.
